[go: up one dir, main page]

HRP20192134T1 - Molekule za vezanje na antigen koji veže egfr, vektori koji ih kodiraju, te njihove primjene - Google Patents

Molekule za vezanje na antigen koji veže egfr, vektori koji ih kodiraju, te njihove primjene Download PDF

Info

Publication number
HRP20192134T1
HRP20192134T1 HRP20192134TT HRP20192134T HRP20192134T1 HR P20192134 T1 HRP20192134 T1 HR P20192134T1 HR P20192134T T HRP20192134T T HR P20192134TT HR P20192134 T HRP20192134 T HR P20192134T HR P20192134 T1 HRP20192134 T1 HR P20192134T1
Authority
HR
Croatia
Prior art keywords
antibody
cancer
variable region
host cell
increased
Prior art date
Application number
HRP20192134TT
Other languages
English (en)
Inventor
Pablo Umana
Ekkehard Moessner
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36777599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20192134(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of HRP20192134T1 publication Critical patent/HRP20192134T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (20)

1. Humanizirano protutijelo anti-EGFR koje se specifično veže na ljudski EGFR, naznačeno time, da navedeno protutijelo obuhvaća sljedeće: (a) varijabilno područje teškog lanca koje obuhvaća sekvencu od SEQ ID NO: 15; i (b) varijabilno područje lakog lanca koje obuhvaća sekvencu od SEQ ID NO:45; i pritom navedeno protutijelo obuhvaća ljudsko Fc područje proizvedeno glikoinženjeringom, koje posjeduje smanjeni broj fukoznih ostataka u usporedbi s oblikom protutijela koji nije proizveden glikoinženjeringom.
2. Protutijelo prema patentnom zahtjevu 1, naznačeno time, da je navedeno Fc područje proizvedeno glikoinženjeringom: (a) kako bi imalo najmanje 70% ne-fukoziliranih oligosaharida; (b) kako bi imalo povećani omjer GlcNAc ostataka naspram fukoznih ostataka u usporedbi s oblikom protutijela koji nije proizveden glikoinženjeringom; (c) kako bi imalo povećani afinitet vezanja Fc receptora u usporedbi s oblikom protutijela koji nije proizveden glikoinženjeringom; (d) kako bi imalo povećanu efektorsku funkciju u usporedbi s oblikom protutijela koji nije proizveden glikoinženjeringom.
3. Protutijelo prema patentnom zahtjevu 2, naznačeno time, da je navedena efektorska funkcija odabrana iz skupine koja se sastoji od povećane Fc-posredovane stanične citotoksičnosti, povećanog vezanja na NK-stanice, povećanog vezanja na makrofage, povećanog vezanja na polimorfonuklearne stanice, povećanog vezanja na monocite, povećanog izravnog signaliziranja induciranog apoptozom, povećane maturacije dendritičke stanice i povećane pripreme za aktivaciju T-stanice.
4. Polipeptid, naznačen time, da on obuhvaća aminokiselinsku sekvencu od varijabilnog područja teškog lanca i lakog lanca od protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 3.
5. Polinukleotid, naznačen time, da on kodira varijabilno područje teškog lanca od protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 4 i varijabilno područje lakog lanca od protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 4.
6. Vektor, naznačen time, da obuhvaća polinukleotid koji kodira varijabilno područje teškog lanca od protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 4 i polinukleotid koji kodira varijabilno područje lakog lanca od protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 4.
7. Vektor prema patentnom zahtjevu 6, naznačen time, da je on policistronički.
8. Stanica domaćina, naznačena time, da ona obuhvaća polinukleotid koji kodira varijabilno područje teškog lanca od protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 4 i polinukleotid koji kodira varijabilno područje lakog lanca od protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 4, ili vektor prema patentnom zahtjevu 6 ili 7.
9. Stanica domaćina prema patentnom zahtjevu 8, naznačena time, da je spomenuta stanica domaćina modificirana inženjeringom kako bi eksprimirala najmanje jednu nukleinsku kiselinu koja kodira polipeptid s aktivitetom β(1,4)-N-acetilglukozaminiltransferaze III.
10. Stanica domaćina prema patentnom zahtjevu 9, naznačena time, da je spomenuta stanica domaćina i dalje modificirana inženjeringom kako bi eksprimirala nukleinsku kiselinu koja kodira polipeptid s aktivitetom Golgi-manosidaze II.
11. Stanica domaćina prema patentnom zahtjevu 9, naznačena time, da je navedeni polipeptid koji ima aktivitet β(1,4)-N-acetilglukozaminiltransferaze III, fuzijski polipeptid koji dodatno sadrži lokalizacijsku Golgi-domenu od heterolognog polipeptida koji je stanovnik Golgi-trakta.
12. Stanica domaćina prema patentnom zahtjevu 11, naznačena time, da je navedena lokalizacijska Golgi-domena odabrana od lokalizacijske domene manosidaze II, lokalizacijske domene β(1,2)-N-acetilglukozaminiltransferaze I, β(1,2)-N-acetilglukozaminiltransferaze II, manosidaze I ili α1-6-jezgra-fukoziltransferaze.
13. Postupak proizvodnje humaniziranog anti-EGFR protutijela podvrgnutog glikoinženjeringu koje ima ljudsko Fc područje modificirano glikoinženjeringom, čime je osposobljeno za natjecanje s protutijelom štakora ICR62 u vezanju na ljudski EGFR, pri čemu spomenuto protutijelo štakora ICR62 obuhvaća varijabilno područje teškog lanca od SEQ ID NO:1 i varijabilno područje lakog lanca od SEQ ID NO:43, naznačen time, da navedeni postupak obuhvaća sljedeće: (a) kultiviranje stanice domaćina prema bilo kojem od patentnih zahtjeva 8 do 12, pod uvjetima koji dopuštaju proizvodnju navedenog protutijela; i (b) izoliranje spomenutog protutijela.
14. Protutijelo koje se specifično veže na ljudski EGFR, naznačeno time, da se navedeno protutijelo može dobiti putem postupka u skladu s patentnim zahtjevom 13 ili se može dobiti pomoću stanice domaćina u skladu s bilo kojim od patentnih zahtjeva 8 do 12.
15. Farmaceutski pripravak, naznačen time, da obuhvaća protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 3 ili 14, te farmaceutski prihvatljiv nosač.
16. Protutijelo prema bilo kojem od patentnih zahtjeva 1 do 3 ili 14, naznačeno time, da se ono upotrebljava kao lijek.
17. Protutijelo prema bilo kojem od patentnih zahtjeva 1 do 3 ili 14, naznačeno time, da se ono upotrebljava u liječenju ili profilaksi raka.
18. Uporaba protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 3 ili 14, naznačena time, da je za proizvodnju farmaceutskog pripravka za liječenje ili profilaksu raka.
19. Protutijelo prema patentnom zahtjevu 17 ili uporaba prema patentnom zahtjevu 18, naznačeno time, da se navedeno protutijelo upotrebljava u terapeutski učinkovitoj količini koja iznosi od 1,0 mg/kg do 15 mg/kg.
20. Protutijelo prema bilo kojem od patentnih zahtjeva 17 do 19 ili uporaba prema patentnom zahtjevu 18 ili 19, naznačeno(a) time, da je navedeni rak odabran iz skupine koja se sastoji od sljedećih: rak mjehura, rak mozga, rak glave i vrata, rak gušterače, rak pluća, rak dojke, rak jajnika, rak debelog crijeva, rak prostate, rak kože i rak bubrega.
HRP20192134TT 2005-02-07 2006-02-07 Molekule za vezanje na antigen koji veže egfr, vektori koji ih kodiraju, te njihove primjene HRP20192134T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65011505P 2005-02-07 2005-02-07
PCT/IB2006/000238 WO2006082515A2 (en) 2005-02-07 2006-02-07 Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
EP06710336.6A EP1871805B1 (en) 2005-02-07 2006-02-07 Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof

Publications (1)

Publication Number Publication Date
HRP20192134T1 true HRP20192134T1 (hr) 2020-02-21

Family

ID=36777599

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20192134TT HRP20192134T1 (hr) 2005-02-07 2006-02-07 Molekule za vezanje na antigen koji veže egfr, vektori koji ih kodiraju, te njihove primjene

Country Status (28)

Country Link
US (8) US7722867B2 (hr)
EP (4) EP2404937A1 (hr)
JP (2) JP5336089B2 (hr)
KR (2) KR101569300B1 (hr)
CN (2) CN103981190A (hr)
AR (1) AR052285A1 (hr)
AU (1) AU2006211037B2 (hr)
BR (1) BRPI0607315B1 (hr)
CA (1) CA2596835C (hr)
CR (2) CR9236A (hr)
DK (1) DK1871805T3 (hr)
ES (1) ES2755976T3 (hr)
HK (1) HK1199470A1 (hr)
HR (1) HRP20192134T1 (hr)
IL (1) IL184498A (hr)
LT (1) LT1871805T (hr)
MA (1) MA29279B1 (hr)
MX (1) MX2007008619A (hr)
NO (1) NO20073662L (hr)
NZ (1) NZ556286A (hr)
PL (1) PL1871805T3 (hr)
PT (1) PT1871805T (hr)
RS (1) RS59761B1 (hr)
RU (2) RU2488597C2 (hr)
SI (1) SI1871805T1 (hr)
TW (1) TWI387602B (hr)
UA (1) UA95068C2 (hr)
WO (1) WO2006082515A2 (hr)

Families Citing this family (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1071700B1 (en) 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
WO2003011878A2 (en) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
DK1871805T3 (da) 2005-02-07 2019-12-02 Roche Glycart Ag Antigenbindende molekyler der binder egfr, vektorer der koder derfor, og anvendelser deraf
AR062223A1 (es) * 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
KR101169243B1 (ko) 2007-06-06 2012-08-02 에프. 호프만-라 로슈 아게 종양 항원에 결합하는 비-표지된 제 1 단클론 항체 및 ｎｉｒ 형광 표지로 표지된 비-교차 반응성 제 2 단클론 항체로 이루어진 조성물
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
BRPI0919382A2 (pt) * 2008-09-26 2016-01-05 Roche Glycart Ag anticorpos bi-específicos anti-egfr/anti-igf-1r
EP2413965A1 (en) * 2009-03-31 2012-02-08 Roche Glycart AG Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan
US20100247484A1 (en) * 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
EP2414391B1 (en) 2009-04-02 2018-11-28 Roche Glycart AG Multispecific antibodies comprising full length antibodies and single chain fab fragments
WO2010112194A1 (en) 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
CA2757426A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-2/anti-c-met antibodies
MX2011010168A (es) 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos, trivalentes.
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
KR20120108967A (ko) 2009-09-16 2012-10-05 제넨테크, 인크. 코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도
WO2011080209A2 (en) * 2009-12-29 2011-07-07 F. Hoffmann-La Roche Ag Novel antibody formulation
IN2012DN06309A (hr) * 2010-01-11 2015-09-25 Alexion Pharma Inc
US20110200595A1 (en) * 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
CN101875697B (zh) * 2010-04-15 2014-04-30 北京天广实生物技术股份有限公司 新型抗egfr人源抗体tgm10的设计及其应用
MX340558B (es) 2010-08-24 2016-07-14 F Hoffmann-La Roche Ag * Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN102153647B (zh) * 2011-01-27 2012-07-04 中国人民解放军军事医学科学院生物工程研究所 一种抗egfr人源化抗体l3-h3及其编码基因与应用
CN103476433A (zh) 2011-02-10 2013-12-25 罗切格利卡特公司 改良的免疫疗法
BR112013019975A2 (pt) 2011-02-28 2017-08-01 Hoffmann La Roche proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
CA2824824A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
US9152861B2 (en) 2011-03-04 2015-10-06 Nec Corporation Individual product identification system, individual product identification method, and device and program used by same
HUE039703T2 (hu) 2011-08-23 2019-01-28 Roche Glycart Ag Bispecifikus antigénkötõ molekulák
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
ES2659764T3 (es) 2011-08-23 2018-03-19 Roche Glycart Ag Moléculas biespecíficas de unión a antígeno activadoras de linfocitos T
RU2605390C2 (ru) 2011-08-23 2016-12-20 Рош Гликарт Аг Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
RU2014114119A (ru) * 2011-09-23 2015-10-27 Рош Гликарт Аг Биспецифические анти-egfr/анти igf-1r-антитела
WO2013113641A1 (en) 2012-01-31 2013-08-08 Roche Glycart Ag Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
KR20140127854A (ko) 2012-02-10 2014-11-04 제넨테크, 인크. 단일-쇄 항체 및 다른 이종다량체
JP2015511702A (ja) 2012-03-02 2015-04-20 ロシュ グリクアート アーゲー Ａｄｃｃ増強抗体を用いた癌治療のための予測バイオマーカー
EP2832363B1 (en) * 2012-03-27 2018-09-19 Green Cross Corporation Epitopes of epidermal growth factor receptor surface antigen and use thereof
CN104918956A (zh) * 2012-05-17 2015-09-16 索伦托治疗有限公司 与egfr结合的抗原结合蛋白
BR112014028368A2 (pt) 2012-06-27 2017-11-14 Hoffmann La Roche método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
KR20150023889A (ko) 2012-06-27 2015-03-05 에프. 호프만-라 로슈 아게 2 개 이상의 상이한 결합 단위를 함유하는 맞춤-제작된 고도로 선별적이고 다중-특이적인 표적화 단위의 선별 및 제조 방법 및 이의 용도
ES2700978T3 (es) 2012-08-07 2019-02-20 Roche Glycart Ag Composición que comprende dos anticuerpos genomanipulados para que tengan una función efectora reducida e incrementada
US10087250B2 (en) 2012-10-08 2018-10-02 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2014114595A1 (en) 2013-01-23 2014-07-31 Roche Glycart Ag Predictive biomarker for cancer treatment with adcc-enhanced antibodies
CN104936985A (zh) 2013-02-26 2015-09-23 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
CA2896370A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
JP6133444B2 (ja) 2013-02-26 2017-05-24 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
EA201591652A1 (ru) 2013-03-06 2016-02-29 Мерримак Фармасьютикалз, Инк. ТАНДЕМНЫЕ БИСПЕЦИФИЧЕСКИЕ Fc-АНТИТЕЛА ПРОТИВ c-MET
KR20150144804A (ko) * 2013-04-22 2015-12-28 글리코토페 게엠베하 낮은 푸코실화를 갖는 항­ｅｇｆｒ 항체를 이용한 항암 치료
MX2016003593A (es) 2013-10-11 2016-06-02 Hoffmann La Roche Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico.
MX2016006301A (es) 2013-11-13 2016-12-16 Zymeworks Inc Construcciones de unión a antígeno monovalente que se dirigen a egfr y/o her2, y sus usos.
RU2016138744A (ru) * 2014-04-10 2018-05-11 Оби Фарма Инк. Антитела, фармацевтические композиции и их применения
EA038958B1 (ru) 2014-08-04 2021-11-15 Ф. Хоффманн-Ля Рош Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10329348B2 (en) 2014-10-23 2019-06-25 Innate Pharma Treatment of cancers using anti-NKG2A agents
FI4141032T3 (fi) 2014-11-20 2024-07-31 Hoffmann La Roche T-solua aktivoivien bispesifisten antigeeniä sitovien molekyylien ja pd-1-akselia sitovien antagonistien yhdistelmähoito
CA2968162A1 (en) 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Common light chains and methods of use
DK3221356T3 (da) 2014-11-20 2020-11-02 Hoffmann La Roche T-celleaktiverende, bispecifikke, antigenbindende molekyler mod folr1 og cd3
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
BR112018000835A2 (pt) 2015-10-02 2018-09-11 Hoffmann La Roche molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo
WO2017055392A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
JP6937746B2 (ja) 2015-10-02 2021-09-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ｃｄ１９×ｃｄ３ｔ細胞活性化抗原結合分子
WO2017055385A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
WO2017055395A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
HK1254967A1 (zh) 2015-10-02 2019-08-02 豪夫迈‧罗氏有限公司 結合間皮素和cd3的雙特異性t細胞活化性抗原結合分子
WO2017055388A2 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
WO2017055393A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
PL3387015T3 (pl) 2015-12-09 2022-02-14 F. Hoffmann-La Roche Ag Przeciwciało anty-CD20 typu II do ograniczania tworzenia przeciwciał przeciwlekowych
ES2837428T3 (es) 2016-01-08 2021-06-30 Hoffmann La Roche Procedimientos de tratamiento de cánceres positivos para CEA usando antagonistas de unión al eje PD-1 y anticuerpos biespecíficos anti-CEA/anti-CD3
HRP20230528T1 (hr) 2016-03-22 2023-08-04 F. Hoffmann - La Roche Ag Bispecifične molekule t stanica aktivirane proteazom
EP3433280B1 (en) 2016-03-22 2023-04-19 F. Hoffmann-La Roche AG Protease-activated t cell bispecific molecules
US10753936B2 (en) 2016-07-22 2020-08-25 Van Andel Research Institute Method of detecting the level of a glycan
US10882918B2 (en) 2016-09-30 2021-01-05 Hoffmann-La Roche Inc. Bispecific T cell activating antigen binding molecules
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
BR112019020168A2 (pt) 2017-03-27 2020-06-02 F. Hoffmann-La Roche Ag Receptores de ligação ao antígeno, células t transduzidas, polinucleotídeo isolado, vetor, kits, métodos para tratar uma doença e para induzir a lise de uma célula alvo e uso do receptor de ligação ao antígeno
CN110461360A (zh) 2017-03-27 2019-11-15 豪夫迈·罗氏有限公司 改进的抗原结合受体形式
CN110382525B (zh) 2017-04-03 2023-10-20 豪夫迈·罗氏有限公司 免疫缀合物
AU2018247767B2 (en) 2017-04-03 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to STEAP-1
EP3606946B1 (en) 2017-04-03 2022-08-24 F. Hoffmann-La Roche AG Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
CR20190434A (es) 2017-04-05 2019-11-01 Hoffmann La Roche Anticuerpos anti-lag3
EP3609537A1 (en) 2017-04-13 2020-02-19 H. Hoffnabb-La Roche Ag An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
CN107881160A (zh) * 2017-08-11 2018-04-06 百奥泰生物科技(广州)有限公司 一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法
WO2019126536A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof
US12139533B2 (en) 2017-12-20 2024-11-12 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-CD200 antibodies
KR102575787B1 (ko) 2017-12-21 2023-09-08 에프. 호프만-라 로슈 아게 Hla-a2/wt1에 결합하는 항체
JP7394058B2 (ja) 2017-12-21 2023-12-07 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規抗原結合部分の特異性試験のためのユニバーサルレポーター細胞アッセイ
EP3731865A1 (en) 2017-12-29 2020-11-04 F. Hoffmann-La Roche AG Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
AU2019218959A1 (en) 2018-02-08 2020-09-03 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
KR20200135510A (ko) 2018-03-29 2020-12-02 제넨테크, 인크. 포유류 세포들에서 젖분비자극 활성의 조절
US20210208156A1 (en) * 2018-06-01 2021-07-08 Musc Foundation For Research Development Glycan analysis of proteins and cells
CN113286822A (zh) 2018-12-21 2021-08-20 豪夫迈·罗氏有限公司 靶向肿瘤的超激动性cd28抗原结合分子
KR102652720B1 (ko) 2018-12-21 2024-03-29 에프. 호프만-라 로슈 아게 Vegf 및 il-1베타에 결합하는 항체 및 이의 사용 방법
CA3123493A1 (en) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Tumor-targeted agonistic cd28 antigen binding molecules
AU2019410075B2 (en) 2018-12-21 2022-08-25 F. Hoffmann-La Roche Ag Antibodies binding to CD3
EP3902829A2 (en) 2018-12-26 2021-11-03 Innate Pharma Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies
TW202115124A (zh) 2019-06-26 2021-04-16 瑞士商赫孚孟拉羅股份公司 結合至cea之新穎抗原結合分子
TW202115115A (zh) 2019-07-02 2021-04-16 瑞士商赫孚孟拉羅股份公司 免疫結合物
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
MX2022001027A (es) 2019-07-26 2022-04-18 Abl Bio Inc Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo.
JP2022543551A (ja) 2019-07-31 2022-10-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｇｐｒｃ５ｄに結合する抗体
MX2022001156A (es) 2019-07-31 2022-02-22 Hoffmann La Roche Anticuerpos que se fijan a gprc5d.
BR112022004972A2 (pt) 2019-09-18 2022-06-28 Genentech Inc Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
BR112022011854A2 (pt) 2019-12-18 2022-09-06 Hoffmann La Roche Anticorpos, polinucleotídeo isolado, célula hospedeira, métodos para produzir um anticorpo e para tratar uma doença, composição farmacêutica, usos do anticorpo e invenção
CN111018990A (zh) * 2020-02-10 2020-04-17 张喜田 一种新型的重组抗表皮生长因子受体单克隆抗体及其应用
JP2023518841A (ja) 2020-03-26 2023-05-08 ジェネンテック， インコーポレイテッド 宿主細胞タンパク質が減少した修飾哺乳動物細胞
BR112022020629A2 (pt) 2020-04-15 2022-11-29 Hoffmann La Roche Polipeptídeo de interleucina-7 (il-7) mutante, imunoconjugado, um ou mais polinucleotídeos isolados, célula hospedeira, métodos para produzir um polipeptídeo il-7 mutante ou um imunoconjugado, para tratar uma doença e para estimular o sistema imunológico, polipeptídeo il-7 mutante, composição farmacêutica, uso do polipeptídeo il-7 mutante e invenção
BR112022022614A2 (pt) 2020-05-11 2023-02-07 Hoffmann La Roche Métodos para estimular uma resposta imune, melhorar uma imunoterapia, tratar uma doença, reduzir crescimento tumoral, produzir um imunoconjugado e produzir uma composição, método de vacinação, imunoconjugados, composição, usos e kits
BR112022024996A2 (pt) 2020-06-08 2022-12-27 Hoffmann La Roche Anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, agente terapêutico, uso do anticorpo e método para tratar um indivíduo com hepatite b
CA3177239A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific antibodies
WO2021255143A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and folr1
US11780920B2 (en) 2020-06-19 2023-10-10 Hoffmann-La Roche Inc. Antibodies binding to CD3 and CD19
PE20230835A1 (es) 2020-06-19 2023-05-19 Hoffmann La Roche Anticuerpos que se unen a cd3
KR20230025783A (ko) 2020-06-19 2023-02-23 에프. 호프만-라 로슈 아게 면역 활성화 Fc 도메인 결합 분자
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
JP7678005B2 (ja) 2020-06-23 2025-05-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２を標的とするアゴニストＣＤ２８抗原結合分子
JP2023533217A (ja) 2020-06-24 2023-08-02 ジェネンテック， インコーポレイテッド アポトーシス耐性細胞株
WO2021260064A1 (en) 2020-06-25 2021-12-30 F. Hoffmann-La Roche Ag Anti-cd3/anti-cd28 bispecific antigen binding molecules
CA3187277A1 (en) 2020-07-10 2022-01-13 F. Hoffmann-La Roche Ag Antibodies which bind to cancer cells and target radionuclides to said cells
BR112023000839A2 (pt) 2020-07-17 2023-02-07 Genentech Inc Anticorpos isolados, ácido nucleico isolado, célula hospedeira, métodos para produzir um anticorpo que se liga a notch2 humano, para tratar um indivíduo com uma doença pulmonar muco-obstrutiva e para reduzir o número de células secretoras em um indivíduo, composição farmacêutica, anticorpo, anticorpo para uso e uso do anticorpo
PE20230998A1 (es) 2020-08-03 2023-06-26 Hoffmann La Roche Receptores de union al antigeno mejorada
JP2023539201A (ja) 2020-08-28 2023-09-13 ジェネンテック， インコーポレイテッド 宿主細胞タンパク質のＣＲＩＳＰＲ／Ｃａｓ９マルチプレックスノックアウト
CA3193163A1 (en) 2020-09-04 2022-03-10 F. Hoffmann-La Roche Ag Antibody that binds to vegf-a and ang2 and methods of use
TW202233671A (zh) 2020-10-20 2022-09-01 美商建南德克公司 Ｐｅｇ結合抗ｍｅｒｔｋ抗體及其使用方法
WO2022090181A1 (en) 2020-10-28 2022-05-05 F. Hoffmann-La Roche Ag Improved antigen binding receptors
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
CR20230385A (es) 2021-01-12 2023-09-25 F Hoffmann La Roche Ag [ Anticuerpos split que se unen a células cancerosas y dirigen radionúclidos a dichas células
AU2022207624A1 (en) 2021-01-13 2023-07-13 F. Hoffmann-La Roche Ag Combination therapy
WO2022169872A1 (en) 2021-02-03 2022-08-11 Genentech, Inc. Multispecific binding protein degrader platform and methods of use
WO2022192647A1 (en) 2021-03-12 2022-09-15 Genentech, Inc. Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
JP2024512709A (ja) 2021-03-30 2024-03-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト プロテアーゼ活性化ポリペプチド
KR20230173164A (ko) 2021-04-19 2023-12-26 제넨테크, 인크. 변형된 포유류 세포
EP4330282A1 (en) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
JP2024521107A (ja) 2021-05-21 2024-05-28 ジェネンテック， インコーポレイテッド 目的の組換え産物を産生するための修飾細胞
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
TW202306985A (zh) 2021-07-12 2023-02-16 美商建南德克公司 降低抗體－脂酶結合之結構
WO2023288241A1 (en) 2021-07-14 2023-01-19 Genentech, Inc. Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
EP4373859A1 (en) 2021-07-22 2024-05-29 F. Hoffmann-La Roche AG Heterodimeric fc domain antibodies
EP4380980A1 (en) 2021-08-03 2024-06-12 F. Hoffmann-La Roche AG Bispecific antibodies and methods of use
CA3234731A1 (en) 2021-10-14 2023-04-20 F. Hoffmann-La Roche Ag New interleukin-7 immunoconjugates
CN118139648A (zh) 2021-10-14 2024-06-04 豪夫迈·罗氏有限公司 用于治疗癌症的替代的PD1-IL7v免疫缀合物
EP4436995A1 (en) 2021-11-25 2024-10-02 F. Hoffmann-La Roche AG Improved antigen binding receptors
EP4437006A1 (en) 2021-11-26 2024-10-02 F. Hoffmann-La Roche AG Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
AR127887A1 (es) 2021-12-10 2024-03-06 Hoffmann La Roche Anticuerpos que se unen a cd3 y plap
CN116333116B (zh) * 2021-12-16 2024-03-05 徕特康(苏州)生物制药有限公司 抗表皮生长因子受体抗体及其制备方法和用途
CN116333117B (zh) * 2021-12-16 2024-04-26 徕特康(苏州)生物制药有限公司 抗表皮生长因子受体抗体及其制备方法和用途
US20230322958A1 (en) 2022-01-19 2023-10-12 Genentech, Inc. Anti-Notch2 Antibodies and Conjugates and Methods of Use
KR20240145492A (ko) 2022-02-11 2024-10-07 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 면역접합체 및 이의 용도
EP4499230A1 (en) 2022-03-25 2025-02-05 F. Hoffmann-La Roche AG Improved chimeric receptors
AR129268A1 (es) 2022-05-11 2024-08-07 Hoffmann La Roche Anticuerpo que se une a vegf-a e il6 y métodos de uso
KR20250044720A (ko) 2022-08-01 2025-04-01 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 면역조절 단백질 및 관련 방법
CN119948048A (zh) 2022-09-29 2025-05-06 豪夫迈·罗氏有限公司 蛋白酶活化的多肽
KR20250075711A (ko) 2022-10-06 2025-05-28 비카라 테라퓨틱스 인크. 다중특이적 단백질 및 관련 방법
CN119998323A (zh) 2022-10-07 2025-05-13 基因泰克公司 使用抗c-c基序趋化因子受体8(ccr8)抗体治疗癌症的方法
TW202423970A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
TW202423969A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
TW202430211A (zh) 2022-10-10 2024-08-01 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
CN120152989A (zh) 2022-11-03 2025-06-13 豪夫迈·罗氏有限公司 抗cd19/抗cd28双特异性抗体的组合疗法
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
CN120187748A (zh) 2022-11-15 2025-06-20 豪夫迈·罗氏有限公司 抗原结合分子
WO2024120516A1 (zh) 2022-12-08 2024-06-13 南京诺唯赞生物科技股份有限公司 特异性结合rsv的抗体
WO2024155807A1 (en) 2023-01-18 2024-07-25 Genentech, Inc. Multispecific antibodies and uses thereof
WO2024153722A1 (en) 2023-01-20 2024-07-25 F. Hoffmann-La Roche Ag Immunoconjugates
WO2024156672A1 (en) 2023-01-25 2024-08-02 F. Hoffmann-La Roche Ag Antibodies binding to csf1r and cd3
US20240269263A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
WO2024184287A1 (en) 2023-03-06 2024-09-12 F. Hoffmann-La Roche Ag Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
WO2024191785A1 (en) 2023-03-10 2024-09-19 Genentech, Inc. Fusions with proteases and uses thereof
WO2024206788A1 (en) 2023-03-31 2024-10-03 Genentech, Inc. Anti-alpha v beta 8 integrin antibodies and methods of use
WO2024208776A1 (en) 2023-04-03 2024-10-10 F. Hoffmann-La Roche Ag Agonistic split antibodies
WO2024208777A1 (en) 2023-04-03 2024-10-10 F. Hoffmann-La Roche Ag All-in-one agonistic antibodies
WO2024231320A1 (en) 2023-05-08 2024-11-14 F. Hoffmann-La Roche Ag Targeted interferon alpha fusion proteins and methods of use
TW202509065A (zh) 2023-05-16 2025-03-01 瑞士商赫孚孟拉羅股份公司 經ｐｄ－１調節之ｉｌ－２免疫結合物及其用途
TW202504918A (zh) 2023-06-01 2025-02-01 瑞士商赫孚孟拉羅股份公司 靶向ｂｃｍａ及ｃｄ２８的雙特異性抗體
WO2024246086A1 (en) 2023-06-01 2024-12-05 F. Hoffmann-La Roche Ag Immunostimulatory antigen binding molecules that specifically bind to bcma
TW202502809A (zh) 2023-06-22 2025-01-16 美商建南德克公司 抗體及其用途
WO2025024334A1 (en) 2023-07-21 2025-01-30 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
WO2025021838A1 (en) 2023-07-26 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025040567A1 (en) 2023-08-18 2025-02-27 F. Hoffmann-La Roche Ag Protease activatable fc domain binding molecules
WO2025068207A1 (en) 2023-09-25 2025-04-03 F. Hoffmann-La Roche Ag ANTIBODY THAT BINDS TO C3bBb
WO2025099120A1 (en) 2023-11-09 2025-05-15 F. Hoffmann-La Roche Ag Multispecific antibodies with conditional activity
WO2025125118A1 (en) 2023-12-11 2025-06-19 F. Hoffmann-La Roche Ag Protease activatable fc domain binding molecules
WO2025125386A1 (en) 2023-12-14 2025-06-19 F. Hoffmann-La Roche Ag Antibodies that bind to folr1 and methods of use
WO2025132503A1 (en) 2023-12-20 2025-06-26 F. Hoffmann-La Roche Ag Antibodies binding to ceacam5
WO2025133290A1 (en) 2023-12-21 2025-06-26 Temper Bio Protein for immune regulation
WO2025133042A2 (en) 2023-12-22 2025-06-26 F. Hoffmann-La Roche Ag Activatable fusion proteins and methods of use

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2820404A (en) 1954-11-23 1958-01-21 Kwei Chung Shu Photoprinting apparatus
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU658396B2 (en) 1991-03-06 1995-04-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric monoclonal antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
JPH11510170A (ja) 1995-07-27 1999-09-07 ジェネンテック インコーポレーテッド タンパク質の処方
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
DE19746874A1 (de) 1997-10-23 1999-04-29 Qiagen Gmbh Verfahren zur Isolierung und Reinigung von Nukleinsäuren an hydrophoben Oberflächen - insbesondere unter Verwendung hydrophober Membranen
EP1071700B1 (en) 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6322980B1 (en) 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
EP2275541B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
WO2000064946A2 (en) * 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
NZ523912A (en) 2000-07-31 2005-03-24 Biolex Inc Expression of biologically active polypeptides in duckweed
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2002034790A1 (en) 2000-10-20 2002-05-02 Idec Pharmaceuticals Corporation Variant igg3 rituxan r and therapeutic use thereof
ES2334494T5 (es) * 2001-05-11 2013-05-29 Ludwig Institute For Cancer Research Ltd. Proteínas de unión específicas y usos de las mismas
IL159225A0 (en) * 2001-06-13 2004-06-01 Genmab As Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
WO2003011878A2 (en) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
MXPA04006357A (es) 2001-12-27 2005-03-31 Glycofi Inc Metodos para disenar estructuras de carbohidrato del tipo de mamifero.
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7897842B2 (en) 2002-03-19 2011-03-01 Plant Research International B.V. GnTIII expression in plants
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
EP1488565A1 (en) 2002-03-28 2004-12-22 Advanced Micro Devices, Inc. Synchronization data detection unit and method
US20030190689A1 (en) 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
US7749753B2 (en) 2002-04-09 2010-07-06 Kyowa Hakko Kirin Co., Ltd Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
US20040132097A1 (en) 2002-06-19 2004-07-08 Bacus Sarah S. Method for predicting response to epidermal growth factor receptor-directed therapy
EP1539966B1 (en) 2002-09-12 2010-06-30 Greenovation Biotech GmbH Protein production method
RU2325186C2 (ru) * 2002-09-27 2008-05-27 Ксенкор, Инк. АНТИТЕЛО, СОДЕРЖАЩЕЕ Fc-ВАРИАНТНУЮ ЧАСТЬ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АНТИТЕЛО, И СПОСОБ ЛЕЧЕНИЯ МЛЕКОПИТАЮЩЕГО
US6938692B2 (en) 2002-12-17 2005-09-06 Halliburton Energy Services, Inc. Permeable cement composition and method for preparing the same
AU2003294912B2 (en) 2002-12-20 2009-06-04 Greenovation Biotech Gmbh Production of heterologous glycosylated proteins in bryophyte cells
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
ES2543734T3 (es) 2003-01-22 2015-08-21 Roche Glycart Ag Constructos de fusión y uso de los mismos para producir anticuerpos con mayor afinidad de unión al receptor de Fc y función efectora
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
EP1701979A2 (en) 2003-12-03 2006-09-20 Xencor, Inc. Optimized antibodies that target the epidermal growth factor receptor
EP2221315A1 (en) * 2003-12-04 2010-08-25 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
DK1871805T3 (da) * 2005-02-07 2019-12-02 Roche Glycart Ag Antigenbindende molekyler der binder egfr, vektorer der koder derfor, og anvendelser deraf
US20100068163A1 (en) * 2005-07-13 2010-03-18 L'oreal Keratin Fibre Coating Composition Comprising a Liquid Fatty Phase and a Tackifying Resin
KR101379568B1 (ko) 2005-08-26 2014-04-08 로슈 글리카트 아게 변형된 세포 신호 활성을 가진 개질된 항원 결합 분자
AR062223A1 (es) * 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
WO2009012175A1 (en) * 2007-07-13 2009-01-22 Ventana Medical Systems, Inc. Antibodies specific for the c-terminal regulatory domain of egfr and their use
BRPI0919382A2 (pt) * 2008-09-26 2016-01-05 Roche Glycart Ag anticorpos bi-específicos anti-egfr/anti-igf-1r

Also Published As

Publication number Publication date
RU2488597C2 (ru) 2013-07-27
DK1871805T3 (da) 2019-12-02
RU2610688C2 (ru) 2017-02-14
KR20070119629A (ko) 2007-12-20
IL184498A0 (en) 2007-10-31
HK1110873A1 (en) 2008-07-25
CA2596835A1 (en) 2006-08-10
US8614065B2 (en) 2013-12-24
US7846432B2 (en) 2010-12-07
TWI387602B (zh) 2013-03-01
IL184498A (en) 2011-08-31
US8097436B2 (en) 2012-01-17
ES2755976T3 (es) 2020-04-24
US20200332012A1 (en) 2020-10-22
HK1199470A1 (en) 2015-07-03
EP2404937A1 (en) 2012-01-11
MX2007008619A (es) 2007-09-11
US7722867B2 (en) 2010-05-25
JP2008529489A (ja) 2008-08-07
KR20140031985A (ko) 2014-03-13
EP2402374A1 (en) 2012-01-04
US9309317B2 (en) 2016-04-12
US20120178106A1 (en) 2012-07-12
NO20073662L (no) 2007-11-05
US20190106497A1 (en) 2019-04-11
PT1871805T (pt) 2019-12-02
CR20120587A (es) 2013-02-05
AU2006211037A1 (en) 2006-08-10
US20110111461A1 (en) 2011-05-12
KR101569300B1 (ko) 2015-11-13
BRPI0607315A2 (pt) 2009-09-01
CR9236A (es) 2007-11-23
US20080279858A9 (en) 2008-11-13
JP5763695B2 (ja) 2015-08-12
BRPI0607315B1 (pt) 2022-05-17
JP5336089B2 (ja) 2013-11-06
NZ556286A (en) 2010-11-26
WO2006082515A2 (en) 2006-08-10
TW200639181A (en) 2006-11-16
PL1871805T3 (pl) 2020-03-31
RS59761B1 (sr) 2020-02-28
RU2013119417A (ru) 2014-11-10
RU2007133439A (ru) 2009-03-20
MA29279B1 (fr) 2008-02-01
CN101115773B (zh) 2015-06-10
US20160304614A1 (en) 2016-10-20
SI1871805T1 (sl) 2020-02-28
AU2006211037B2 (en) 2012-05-24
EP1871805B1 (en) 2019-09-25
US9957326B2 (en) 2018-05-01
KR101467566B1 (ko) 2014-12-02
US20140227253A1 (en) 2014-08-14
LT1871805T (lt) 2019-12-10
EP3660049A1 (en) 2020-06-03
CA2596835C (en) 2019-08-20
CN103981190A (zh) 2014-08-13
US20090186019A1 (en) 2009-07-23
CN101115773A (zh) 2008-01-30
WO2006082515A3 (en) 2007-06-14
EP1871805A2 (en) 2008-01-02
JP2013165711A (ja) 2013-08-29
AR052285A1 (es) 2007-03-07
US20060269545A1 (en) 2006-11-30
UA95068C2 (uk) 2011-07-11

Similar Documents

Publication Publication Date Title
HRP20192134T1 (hr) Molekule za vezanje na antigen koji veže egfr, vektori koji ih kodiraju, te njihove primjene
CN106459195B (zh) 抗人白介素-1受体辅助蛋白(il1 rap)抗体及其用途
AU2016339832B2 (en) Antibody agents specific for human CD19 and uses thereof
CN112867507B (zh) 新型抗sirpa抗体
EP3363818B1 (en) Method for producing antibody ch3 domain heterodimeric mutant pair using yeast mating
TWI851585B (zh) 抗steap1抗原結合蛋白
JP2009545325A5 (hr)
JP2013165711A5 (hr)
CN111423511A (zh) 与pd-1结合的抗原结合蛋白
EP3178847B1 (en) Anti-tnf-alpha fully human monoclonal antibodies with low immunogenicity and application thereof
WO2009028663A1 (ja) 抗Claudin-3抗体
AU2018303254B2 (en) Generating multispecific antibody mixtures and methods of uses thereof
EP4173638A1 (en) Anti-cd70 antibody and application thereof
JP2023179558A (ja) 抗ｐｄ―ｌ１抗体およびその用途
CN111378044B (zh) 抗体融合蛋白、制备方法及其应用
CN108025065A (zh) 与cd123结合的抗体治疗方法
US20250019440A1 (en) Immunomodulatory trispecific t cell engager fusion proteins
CN117279948A (zh) 与cd47和pd-l1特异性结合的双特异性抗体
EP4242231A1 (en) Anti-siglec-15 antibody and application thereof in preparing drug
CN114656562B (zh) 结合人和猴cd3的抗体及其应用
CN103265631B (zh) 一种抗人crt单克隆抗体的重链和轻链可变区
CN109641958A (zh) huTNFR1相互作用的单价抑制剂
WO2008152537A2 (en) Humanized monoclonal antibodies against human epidermal growth factor receptor, use and method thereof
CN119137154A (zh) 抗叶酸受体α抗体及使用方法
US10611833B2 (en) Humanized anti-human epidermal growth factor receptor antibody and application thereof